Decrease in BMI Linked to Increased Risk for Severe Exacerbations, All-Cause Mortality in COPD
Among persons with COPD whose BMI decreased over a 4-year follow-up, mortality risk rose 70% compared with those whose BMI remained the same, researchers reported.
Steven Nissen, MD, Discusses the "Sweet Spot" for Bempedoic Acid Among Non-Statin Therapies
The CLEAR Outcomes PI explains the patient selection approach for bempedoic acid, now approved to reduce risk of CV events in addition to lowering LDL-C.
Shingrix Nearly 80% Effective Against Shingles in Older Adults up to 11 Years Post-Vaccination
Vaccine efficacy remained high at 82% at year 11 following vaccination, according to new long-term data.
RSV Disease Severity Comparable to Unvaccinated COVID-19, Flu: Daily Dose
Your daily dose of the clinical news you may have missed.
8 Questions on Management of Chronic Coronary Disease: A Guideline Topline Quiz
Based on the updated 2023 AHA/ACC recommendations, the 9-question quiz tests what you know about the most current approaches to CCD treatment.
How the CLEAR Outcomes Trial Made CV Risk Reduction History, with Lead Investigator Steven Nissen, MD
Bempedoic acid became the first nonstatin LDL-C lowering medication indicated to reduce CV risk in both primary and secondary prevention. Nissen explains how.
Risk for CHD Higher for Women who Binge Drink vs Men: Daily Dose
Navigating the New Wave of Antiobesity Medications: What Primary Care Clinicians Should Know
With the rise in demand for newer antiobesity medications, clinicians may face more questions from patients. Here, a primer on the drawbacks and benefits to keep in mind.
Tirzepatide Significantly Reduces OSA Symptoms in Phase 3 Trials, Lilly Looks Toward Mid-2024 Regulatory Submission
Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.
Tezepelumab for COPD Moves into Phase 3 Planning
Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.
GSK Announces FDA PDUFA Date for 5-in-1 Meningococcal Vaccine Based on Acceptance of BLA
The FDA expects to take action on the GSK BLA for its pentavalent MenB vaccine by February 14, 2025.
Elevated Lp(a) Level Increased ASCVD Risk Regardless of Age, Sex, Race/Ethnicity in Pooled Primary Prevention Cohort
Elevated lipoprotein(a) was independently associated with increased ASCVD risk across primary prevention subgroups including among those with LDL-C of 70 mg/dL.
Zilebesiran Reduces SBP on Background SOC in Uncontrolled HTN: Daily Dose
Triptans and Ischemic Events: A New Study Parses the Risk
Labeling for triptan medications warns of potential for ischemic events but is the concern theoretical or real? A new study tests the association.
Breathlessness in Middle-Aged Adults Linked to Overweight/Obesity, Stress, and Respiratory Disease
Results of a recent study support the importance of lifestyle interventions to reduce the burden of breathlessness in middle-aged adults.
Advanced-Stage CKD Prevalence Rising Rapidly Worldwide: Multidimensional Modeling Study
The overall CKD population will reach 125 million by 2032 across 8 industrialized nations, with significant clinical, social, economic, and environmental costs.
Semaglutide Improves Functional Status, Body Weight in Patients with HFpEF, Obesity, T2D: Daily Dose
Obesity & Chronic Pain Management: An Expert Discussion
Monu Khanna, MD, discusses challenges in managing pain in patients with obesity, effective pharmacological and nonpharmacological therapies, and more.
AbbVie Announces Late Breaking Data at AAN to Support Atogepant Long-Term Safety, Efficacy for Migraine Prevention
AAN: 70% of participants reached ≥50% reduction in MMDs at weeks 13-16 that was consistent for 48 weeks in an interim analysis of a 156-week open-label trial.
Novel Antiobesity Drug Significantly Improves Body Composition, Bone Mineral Content in Phase 2 Study
LPCN 2401, a combination anabolic androgen receptor agonist and α-tocopherol, decreased fat mass by 6.7% and increased lean mass by 4.4% over 36 weeks, said Lipocine, Inc.
